Long-term clinical outcomes in lysosomal acid lipase deficiency: Fibrosis regression with sebelipase alfa therapy.

Background: Lysosomal acid lipase deficiency (LAL-D) is a rare autosomal recessive disorder caused by mutations in the Methods: We present a case of a 41-year-old female with biopsy-confirmed CESD and cirrhosis, diagnosed in childhood. She was enrolled in the 2015 phase 3 clinical trial for Kanuma and continued on biweekly ERT thereafter. Serial liver imaging and biopsies were performed between 2002 and 2023 to monitor fibrosis progression or regression. Results: Initial fibrosis staging progressed to cirrhosis (Metavir F4) by 2016. Despite persistently elevated lipid levels (LDL 3.81 mmol/L in 2025), MR elastography and liver biopsy in 2023 demonstrated regression of fibrosis to stage 1-2 and histologic signs of cirrhosis reversal while she was taking Kanuma. This occurred in the absence of significant hepatic steatosis or iron overload. Conclusions: This case highlights the potential for long-term Kanuma therapy to reverse liver fibrosis in LAL-D, even with ongoing dyslipidemia. While early initiation of ERT may optimize outcomes, this case supports its continued use in advanced disease stages. Further research is needed to assess the long-term metabolic and histologic benefits of ERT in LAL-D patients.